Ingevity Corp current report, 10 December 2018

Открыть документ

Business Context and Reporting Period

Company: Ingevity Corp
Filing Type: Form 8-K (Current Report)
Date of Report: December 10, 2018
Event: Entry into a Material Definitive Agreement to acquire Perstorp UK Ltd.

Key Financial Metrics

This filing announces a strategic acquisition rather than reporting periodic financial results. Consequently, specific revenue, profit, cash flow, margin, or debt figures for the reporting period are not provided in this document.

  • Transaction Value: EUR 570,913,000 (Purchase Price).
  • Adjustments: Purchase Price is subject to deductions for Intercompany Debt Amount and Seller's Transaction Costs, plus accrued interest.
  • Financing Plan: Expected to be funded through a combination of borrowings under existing credit facilities and cash on hand.

Material Changes

The primary material change is the agreement to acquire Perstorp UK Ltd., which includes the Seller's entire caprolactone business (Capatm). This transaction represents a significant expansion of Ingevity's specialty chemicals portfolio. The filing notes that neither the target business nor the Seller has a material relationship with Ingevity, and the transaction is not affiliated.

Guidance, Outlook, and Risks

Outlook and Timing:

  • Closing Date: Expected to close late in the first quarter of 2019.
  • Conditions: Closing is subject to regulatory approvals (including anti-trust) but is not subject to financing conditions.
  • Post-Closing: A transitional services agreement is intended, where the Seller will provide innovation, technical support, warehousing, distribution, IT, and administrative services.
Risks and Contingencies:
  • Failure to obtain necessary regulatory approvals in the anticipated timeframe or at all.
  • Failure to realize expected benefits or synergies from the acquisition.
  • Integration risks and significant transaction costs.
  • Unknown or understated liabilities.
  • General economic conditions, currency exchange rates, and raw material supply (specifically crude tall oil).
  • Operational risks including natural disasters, labor difficulties, and environmental liabilities.
Management Commentary:

Management believes the warranties, covenants, and conditions are customary for a transaction of this size. Investors are cautioned not to rely on forward-looking statements regarding the acquisition's benefits or timing as actual results may differ materially.

Investor Verification Checklist

  • Verify the final closing date and whether all regulatory approvals were obtained by Q1 2019.
  • Confirm the final purchase price after adjustments for intercompany debt and transaction costs.
  • Monitor the impact of the acquisition on Ingevity's leverage ratios and credit facility availability.
  • Review subsequent filings for details on the transitional services agreement and integration progress.
  • Assess the performance of the Capatm business post-acquisition against management's synergy expectations.